Yidu Tech, Inc. (2158) AI Stock Analysis

• Market Cap: HK$5.42B
• Dividend Yield: N/A
• Average Volume (3M): 16.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -12.31%
• EPS Growth: 41.72%
• Country: HK
• Employees: 866
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.08
• Shares Outstanding: 1,067,446,900
• 10 Day Avg. Volume: 13,676,180
• 30 Day Avg. Volume: 16,154,572
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.00
• Price Target Upside: 2.56% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: HK$6.00 ▲(2.56% Upside)

Yidu Tech, Inc. faces significant challenges in financial performance, with declining revenue and profitability issues being the most significant factors. Technical analysis shows mixed signals, with no strong trend. Valuation is poor due to a negative P/E ratio and lack of dividend yield, further impacting the overall score.

Yidu Tech, Inc. Business Overview & Revenue Model

Company Description

Yidu Tech Inc. provides healthcare solutions built on big data and artificial intelligence technologies in Mainland China, Brunei, and internationally. The company operates through Big Data Platform and Solutions, Life Sciences Solutions, Health Management Platform and Solutions, and Others segments. The Big Data Platform and Solutions segment offers data intelligence platforms and data analytics-driven solutions to hospitals, other healthcare institutions, regulators, and policy makers. This segment also provides applications and solutions to hospitals focusing on research, clinical diagnosis and treatment, and hospital operations management; DPAP/Eywa platforms for hospitals and medical institutions; and intelligent research and clinical and management solutions to medical customers. The Life Sciences Solutions segment offers analytics-driven clinical development, real-world evidence (RWE)-based research, and digital commercialization solutions to pharmaceutical, biotech, medical device, and other companies. The Health Management Platform and Solutions segment provides health management platform application and solution services; and insurance technology and solutions to insurance companies, agencies, and related regulators and policy makers. This segment also engages in the distribution of insurance companies products; and sale of pharmaceutical products and related hardware and other services. The Others segment is involved in the sale of computer hardware. The company also engages in the sale of medical devices; insurance brokerage activities; and medical and computer technology development activities. Yidu Tech Inc. was incorporated in 2014 and is headquartered in Beijing, China.

How the Company Makes Money

Yidu Tech generates revenue through multiple key streams, primarily by offering subscription-based software services and analytics solutions to healthcare institutions and organizations. The company charges clients for access to its data platforms and analytics tools, which are critical for improving operational efficiency and patient care. Additionally, Yidu Tech engages in partnerships with healthcare providers and pharmaceutical companies to develop tailored solutions, which can also provide lucrative revenue opportunities. The company may also benefit from government contracts and initiatives aimed at enhancing healthcare infrastructure, contributing significantly to its earnings.

Yidu Tech, Inc. Financial Statement Overview

Summary

Yidu Tech, Inc. faces challenges in revenue growth and profitability, with negative net profit and EBIT margins. The balance sheet is stable with low leverage, but profitability needs improvement. Cash flow management is crucial, with negative operating cash flows needing to turn positive.

Income Statement

Yidu Tech, Inc. has experienced declining revenue growth, with a negative growth rate of -8.34% in the most recent year. The company also faces challenges in profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin has decreased from the previous year, indicating pressure on cost management. Overall, the income statement reflects a need for improvement in revenue generation and cost control.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.03, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio remains strong at approximately 83.6%, suggesting a solid equity base relative to total assets. Despite the low leverage, the company needs to improve profitability to enhance shareholder returns.

Cash Flow

Yidu Tech, Inc. has shown a significant increase in free cash flow growth, but the operating cash flow remains negative, indicating operational challenges. The free cash flow to net income ratio is positive, suggesting that the company is generating cash relative to its net losses. However, the negative operating cash flow to net income ratio highlights the need for better cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	780.04M	714.98M	807.08M	804.70M	1.24B	867.04M
Gross Profit	319.82M	239.18M	339.44M	274.50M	396.89M	327.34M
EBITDA	-314.96M	-89.62M	-170.77M	-579.98M	-715.70M	-3.65B
Net Income	-162.62M	-117.79M	-194.94M	-627.97M	-762.32M	-3.70B
Balance Sheet
Total Assets	4.67B	4.69B	4.82B	4.91B	4.72B	5.25B
Cash, Cash Equivalents and Short-Term Investments	3.39B	3.30B	3.70B	3.75B	3.77B	4.63B
Total Debt	55.91M	129.54M	95.20M	14.13M	52.16M	26.43M
Total Liabilities	680.97M	711.37M	732.21M	755.36M	715.34M	497.71M
Stockholders Equity	3.93B	3.92B	4.02B	4.08B	3.99B	4.73B
Cash Flow
Free Cash Flow	-154.49M	-350.78M	-367.20M	-374.60M	-672.14M	-350.73M
Operating Cash Flow	-152.54M	-248.81M	-326.38M	-357.01M	-614.68M	-331.68M
Investing Cash Flow	-213.97M	116.71M	466.90M	-2.34B	3.39B	-3.87B
Financing Cash Flow	35.33M	20.04M	82.21M	361.45M	-35.23M	4.26B

Yidu Tech, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2158, the sentiment is Negative. The current price of 5.85 is below the 20-day moving average (MA) of 6.00, below the 50-day MA of 6.28, and below the 200-day MA of 5.97, indicating a bearish trend. The MACD of -0.12 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 30.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2158.

Yidu Tech, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	73 Outperform	6.22B	6.97	11.25%	6.20%	-20.64%	-25.39%
1763	73 Outperform	4.97B	10.85	―	2.44%	13.59%	6.31%
2159	54 Neutral	372.40M	-8.29	-63.60%	―	-5.38%	63.93%
2251	53 Neutral	1.51B	-7.83	-20.13%	―	-32.17%	-1.20%
2616	49 Neutral	11.24B	-25.06	-25.07%	―	-55.64%	-158.67%
2158	42 Neutral	HK$5.42B	―	-2.97%	―	-12.31%	41.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Yidu Tech, Inc. Corporate Events

Yidu Tech Inc. Successfully Passes All Resolutions at AGM

Yidu Tech Inc. announced that all proposed resolutions were passed at its Annual General Meeting held on August 29, 2025. The resolutions included the adoption of financial statements, re-election of directors, and re-appointment of auditors. The approval of these resolutions reflects shareholder support for the company’s current management and strategic direction.

The most recent analyst rating on (HK:2158) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.

Yidu Tech Inc. Announces 2025 Annual General Meeting Agenda

Yidu Tech Inc. has announced its upcoming annual general meeting, which will take place in Beijing on August 29, 2025. The meeting’s agenda includes the adoption of the company’s audited financial statements for the year ended March 31, 2025, re-election of directors, and re-appointment of PricewaterhouseCoopers as the company’s auditor. Additionally, the meeting will address resolutions concerning the company’s share capital, authorizing the directors to allot and issue shares and handle treasury shares. These resolutions are aimed at providing the company with flexibility in managing its capital structure, potentially impacting its market operations and stakeholder interests.

Yidu Tech Inc. Announces Share Award Grant to Boost Long-term Growth

Yidu Tech Inc. has announced the grant of 3,568,700 Award Shares under its Post-IPO Share Award Scheme, which constitutes approximately 0.34% of the total issued shares. These shares are distributed among 115 grantees, including 114 employees and one service provider, with no consideration required for the shares. The vesting periods for these awards range from 2025 to 2029, with some shares having a vesting period of less than 12 months due to administrative reasons. The company believes this grant will incentivize grantees to contribute to its long-term growth and development.

Yidu Tech Inc. Reports Annual Results and Advances in Medical AI

Yidu Tech Inc. announced its annual results for the fiscal year ending March 31, 2025, reporting a decline in revenue and gross profit compared to the previous year. Despite the financial losses, the company is at the forefront of the medical AI industry, with its proprietary ‘AI Medical Brain’, YiduCore, making significant technological advancements and achieving full-chain compatibility with high-end chips. Yidu Tech is leading the transition from technical validation to industrial value realization in medical AI, with its solutions being implemented in over 30 leading hospitals, and is poised for substantial growth opportunities as it continues to expand its customer network and strategic partnerships.

The most recent analyst rating on (HK:2158) stock is a Buy with a HK$8.00 price target. To see the full list of analyst forecasts on Yidu Tech, Inc. stock, see the HK:2158 Stock Forecast page.